Genzyme Tries to Convince Sanofi-Aventis Its MS Drug Is Worth More
The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a b…